ArticleAlcoholism, clinical and experimental research2022
Medication prescribing for alcohol use disorders during alcohol-related encounters in a Colorado regional healthcare system.
Article in Alcoholism, clinical and experimental research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 15 citations in OpenAlex.
- Discontinuation of medications for alcohol use disorder in the United States: Patient, prescriber and medication predictors.Addiction (Abingdon, England) · 2026Observational
- Race, Ethnicity, and Language Differences in Inpatient Discharge Prescriptions for Alcohol Use Disorder at an Academic Medical Center.Journal of general internal medicine · 2026Article
- Mental disorders in the Black population: a scoping review.Frontiers in public health · 2026Article
- Trends, timing, and predictors of alcohol use disorder treatment among US adult cancer survivors.Journal of internal medicine · 2025Article
- Epidemiology of Substance-Related Admissions to ICUs in the United States.Critical care medicine · 2025Article
- Predictors of naltrexone prescribing for alcohol use disorder from the emergency department.Alcohol, clinical & experimental research · 2025Article
- Primary Care Visit Frequency Is Associated With Diagnosis But Not Pharmacotherapy Prescribing for Patients With Alcohol Use Disorder : AUD Pharmacotherapy Prescribing in Primary Care.The journal of behavioral health services & research · 2025Article
- Health disparities in cirrhosis care and liver transplantation.Nature reviews. Gastroenterology & hepatology · 2025Review
- Disparities in Treatment for Alcohol Use Disorder Among All of Us Participants.The American journal of psychiatry · 2024Article
- Medications for Alcohol Use Disorder: Rates and Predictors of Prescription Order and Fill in Outpatient Settings.Journal of general internal medicine · 2024Article
- Outcomes After Initiation of Medications for Alcohol Use Disorder at Hospital Discharge.JAMA network open · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
rationaleInvestigations show that medications for alcohol use disorders (MAUD) reduce heavy drinking and relapses. However, only 1.6% of individuals with alcohol use disorders (AUD) receive MAUD across care settings. The epidemiology of MAUD prescribing in the acute care setting is incompletely described. We hypothesized that MAUD would be under prescribed in inpatient acute care hospital settings compared to the outpatient, emergency department (ED), and inpatient substance use treatment settings.
methodsWe evaluated electronic health record (EHR) data from adult patients with an International Classification of Diseases, 10th revision (ICD-10) alcohol-related diagnosis in the University of Colorado Health (UCHealth) system between January 1, 2016 and 31 December, 2019. Data from patients with an ICD-10 diagnosis code for opioid use disorder and those receiving MAUD prior to their first alcohol-related episode were excluded. The primary outcome was prescribing of MAUD, defined by prescription of naltrexone, acamprosate, and/or disulfiram. We performed bivariate and multivariate analyses to identify independent predictors of MAUD prescribing at UCHealth.
resultsWe identified 48,421 unique patients with 136,205 alcohol-related encounters at UCHealth. Encounters occurred in the ED (42%), inpatient acute care (17%), inpatient substance use treatment (18%), or outpatient primary care (12%) settings. Only 2270 (5%) patients received MAUD across all settings. Female sex and addiction medicine consults positively predicted MAUD prescribing. In contrast, encounters outside inpatient substance use treatment, Hispanic ethnicity, and black or non-white race were negative predictors of MAUD prescribing. Compared to inpatient substance use treatment, inpatient acute care hospitalizations for AUD was associated with a 93% reduced odds of receiving MAUD.
conclusionsAUD-related ED and inpatient acute care hospital encounters in our healthcare system were common. Nevertheless, prescriptions for MAUD were infrequent in this population, particularly in inpatient settings. Our findings suggest that the initiation of MAUD for patients with alcohol-related diagnoses in acute care settings deserves additional evaluation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.